

Produktinformation



Forschungsprodukte & Biochemikalien
Zellkultur & Verbrauchsmaterial
Diagnostik & molekulare Diagnostik
Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien T. +43(0)1 489 3961-0 F. +43(0)1 489 3961-7 <u>mail@szabo-scandic.com</u> www.szabo-scandic.com

PRODUCT INFORMATION



7IY28

Item No. 38864

Formal Name:	1-(4'-((5-cyclopropyl-3-(2,6- dichlorophenyl)isoxazol-4-yl) methoxy)-[1,1'-biphenyl]-3-yl) cyclopropane-1-carboxylic acid	0	
MF:	C ₂₀ H ₂₃ Cl ₂ NO ₄	N \ .0.	^
FW:	520.4		\downarrow
Purity:	≥90%		
UV/Vis.:	λ _{max} : 265 nm	CI	
Supplied as:	A solid		
Storage:	-20°C		
Stability:	≥3 years	\sim	\checkmark

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

ZLY28 is supplied as a solid. A stock solution may be made by dissolving the ZLY28 in the solvent of choice, which should be purged with an inert gas. ZLY28 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of ZLY28 in these solvents is approximately 30 mg/ml.

Description

ZLY28 is a farnesoid X receptor (FXR) agonist and an inhibitor of fatty acid binding protein 1 (FABP1).¹ It selectively induces reporter gene expression in HepG2 cells expressing human FXR (EC₅₀ = 143 nM) over cells expressing 19 other receptors (EC₅₀s = >10,000 nM for all). ZLY28 selectively inhibits FABP1 (IC₅₀ = 2.7 μ M) over FABP3 (IC₅₀ = >30 μ M) but also inhibits FABP4 (IC₅₀ = 6.3 μ M). *In vivo*, ZLY28 (20 mg/kg) induces FXR-related gene expression in the ileum but not the liver in a mouse model of carbon tetrachlorideinduced non-alcoholic steatohepatitis (NASH). It also reduces hepatocyte ballooning, as well as hepatic lobular inflammation and steatosis in the same model.

Reference

1. Ren, Q., Chen, Y., Zhou, Z., et al. Discovery of the first-in-class intestinal restricted FXR and FABP1 dual modulator ZLY28 for the treatment of nonalcoholic fatty liver disease. J. Med. Chem. 66(9), 6082-6104 (2023).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uver agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 07/13/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM